OpenEvidence raised a $250 million Series D on January 21, 2026 at a $12 billion valuation, co-led by Thrive Capital and DST Global.1 Pulse 2.0 2026-01-21 OpenEvidence raised a $250 million Series D on January 21, 2026 at a $12 billion valuation, led by Thrive Capital and DST Global, providing citation-linked answers drawn only from peer-reviewed medical literature, with about $100 million annual revenue and total funding near $700 million. Open source The round roughly doubled the company's valuation from about $6 billion three months earlier and brought total funding over the prior year to around $700 million.2 Healthcare.digital 2026-01-22 The round doubled OpenEvidence's valuation from $6 billion three months earlier; about 40% of US physicians use the free platform across 10,000 hospitals with over 20 million monthly consultations, and revenue comes primarily from pharmaceutical advertising during answer generation, with content partnerships including NEJM, AMA, JAMA and NCCN. Open source The stake: a clinical decision-support tool used by roughly 40 percent of US physicians is now among the most valuable healthcare AI companies, on a business model that gives the product away and monetizes pharmaceutical advertising.2 Healthcare.digital 2026-01-22 The round doubled OpenEvidence's valuation from $6 billion three months earlier; about 40% of US physicians use the free platform across 10,000 hospitals with over 20 million monthly consultations, and revenue comes primarily from pharmaceutical advertising during answer generation, with content partnerships including NEJM, AMA, JAMA and NCCN. Open source We assess with moderate confidence that OpenEvidence's valuation rests on physician reach rather than proven revenue, and that its unresolved regulatory and liability posture is the largest risk the price does not yet reflect.

What is behind the number

OpenEvidence positions itself as a medical search engine that returns real-time, citation-linked answers drawn exclusively from peer-reviewed medical literature, described as a brain extender for clinicians and trained on medical journals rather than the open internet.1 Pulse 2.0 2026-01-21 OpenEvidence raised a $250 million Series D on January 21, 2026 at a $12 billion valuation, led by Thrive Capital and DST Global, providing citation-linked answers drawn only from peer-reviewed medical literature, with about $100 million annual revenue and total funding near $700 million. Open source That grounding is enforced by content partnerships with the New England Journal of Medicine, the American Medical Association, JAMA Network journals, and the National Comprehensive Cancer Network, giving the tool licensed access to the sources clinicians already trust.2 Healthcare.digital 2026-01-22 The round doubled OpenEvidence's valuation from $6 billion three months earlier; about 40% of US physicians use the free platform across 10,000 hospitals with over 20 million monthly consultations, and revenue comes primarily from pharmaceutical advertising during answer generation, with content partnerships including NEJM, AMA, JAMA and NCCN. Open source

The reach is the asset investors are pricing. About 40 percent of US physicians use the platform, more than 750,000 verified doctors have signed up, and the tool logs over 20 million clinical consultations a month across 10,000 hospitals and medical centers.2 Healthcare.digital 2026-01-22 The round doubled OpenEvidence's valuation from $6 billion three months earlier; about 40% of US physicians use the free platform across 10,000 hospitals with over 20 million monthly consultations, and revenue comes primarily from pharmaceutical advertising during answer generation, with content partnerships including NEJM, AMA, JAMA and NCCN. Open source Against that adoption, disclosed revenue is roughly $100 million a year, meaning the $12 billion valuation is about 120 times revenue.1 Pulse 2.0 2026-01-21 OpenEvidence raised a $250 million Series D on January 21, 2026 at a $12 billion valuation, led by Thrive Capital and DST Global, providing citation-linked answers drawn only from peer-reviewed medical literature, with about $100 million annual revenue and total funding near $700 million. Open source We assess with high confidence that the valuation is an adoption multiple, not an earnings multiple, because the reported revenue cannot on its own support the price.

The monetization model is the part that reframes the story. The platform is free to verified clinicians, and revenue derives primarily from pharmaceutical advertising surfaced during answer generation.2 Healthcare.digital 2026-01-22 The round doubled OpenEvidence's valuation from $6 billion three months earlier; about 40% of US physicians use the free platform across 10,000 hospitals with over 20 million monthly consultations, and revenue comes primarily from pharmaceutical advertising during answer generation, with content partnerships including NEJM, AMA, JAMA and NCCN. Open source That is a familiar structure from consumer search transplanted into the clinical setting, and it is the mechanism that lets the company chase reach first and revenue second. The growth curve that curve produced is steep: consultations climbed from a few million a month to over 20 million a month within roughly a year, and the same doubling of the valuation, from about $6 billion to $12 billion in three months, tracks that usage rather than any change in earnings.2 Healthcare.digital 2026-01-22 The round doubled OpenEvidence's valuation from $6 billion three months earlier; about 40% of US physicians use the free platform across 10,000 hospitals with over 20 million monthly consultations, and revenue comes primarily from pharmaceutical advertising during answer generation, with content partnerships including NEJM, AMA, JAMA and NCCN. Open source We assess with moderate confidence that investors are underwriting the assumption that a captive audience of prescribing physicians is worth more per user than a general consumer, because the advertiser paying to reach them, a drugmaker, values that moment of clinical decision highly. The risk in that same logic is that the more valuable the ad moment, the sharper the conflict between what serves the advertiser and what serves the patient.

Second order effects and the ledger

Who gains. OpenEvidence's investors gain a doubled mark in a quarter and a company with distribution most healthcare startups cannot buy.2 Healthcare.digital 2026-01-22 The round doubled OpenEvidence's valuation from $6 billion three months earlier; about 40% of US physicians use the free platform across 10,000 hospitals with over 20 million monthly consultations, and revenue comes primarily from pharmaceutical advertising during answer generation, with content partnerships including NEJM, AMA, JAMA and NCCN. Open source Pharmaceutical marketers gain a targeted channel that reaches prescribing physicians at the exact moment of clinical decision, the highest-intent point in the funnel.2 Healthcare.digital 2026-01-22 The round doubled OpenEvidence's valuation from $6 billion three months earlier; about 40% of US physicians use the free platform across 10,000 hospitals with over 20 million monthly consultations, and revenue comes primarily from pharmaceutical advertising during answer generation, with content partnerships including NEJM, AMA, JAMA and NCCN. Open source The publishing partners, NEJM, AMA, and the specialty journals, gain a licensing revenue line as their content becomes the substrate for an AI product.2 Healthcare.digital 2026-01-22 The round doubled OpenEvidence's valuation from $6 billion three months earlier; about 40% of US physicians use the free platform across 10,000 hospitals with over 20 million monthly consultations, and revenue comes primarily from pharmaceutical advertising during answer generation, with content partnerships including NEJM, AMA, JAMA and NCCN. Open source

Who loses, or bears the risk. The physician using the tool carries the medical-legal exposure: an answer synthesized by a model, however well grounded in journals, is consumed inside a decision the clinician remains liable for. We assess with moderate confidence that the pharma-funded model creates a structural tension, because the party paying for the product is not the party the product ostensibly serves, and any perception that advertising influences clinical answers would be corrosive to the trust the whole business depends on. General-purpose assistants such as ChatGPT also lose ground here, because a tool grounded only in peer-reviewed sources with citation trails is a stronger fit for a setting where an unsourced claim is a liability.1 Pulse 2.0 2026-01-21 OpenEvidence raised a $250 million Series D on January 21, 2026 at a $12 billion valuation, led by Thrive Capital and DST Global, providing citation-linked answers drawn only from peer-reviewed medical literature, with about $100 million annual revenue and total funding near $700 million. Open source

The counter-case

The bull case is that reach at this scale is itself defensible and that revenue follows engagement, as it did for consumer search. The counter-case is that the two hardest questions are still open. First, liability: a citation-linked answer reduces but does not eliminate the risk of a wrong or outdated synthesis reaching a patient, and the reported figures say nothing about how errors are handled or who is accountable when one causes harm.1 Pulse 2.0 2026-01-21 OpenEvidence raised a $250 million Series D on January 21, 2026 at a $12 billion valuation, led by Thrive Capital and DST Global, providing citation-linked answers drawn only from peer-reviewed medical literature, with about $100 million annual revenue and total funding near $700 million. Open source Second, the funding source: a free clinical tool paid for by drug advertising invites scrutiny over whether commercial incentives can be fully walled off from the answers physicians see.2 Healthcare.digital 2026-01-22 The round doubled OpenEvidence's valuation from $6 billion three months earlier; about 40% of US physicians use the free platform across 10,000 hospitals with over 20 million monthly consultations, and revenue comes primarily from pharmaceutical advertising during answer generation, with content partnerships including NEJM, AMA, JAMA and NCCN. Open source For the valuation to hold, OpenEvidence must convert reach into durable revenue without a trust rupture on either front. A single well-publicized case of a harmful answer, or evidence that advertising shaped clinical content, would threaten the adoption that is the entire thesis. The revenue and usage figures here are company-reported and not independently audited, and should be read with that caveat.

What to watch

  • Revenue closes the gap to the multiple. If disclosed revenue moves materially above the reported $100 million through 2026, the adoption-to-earnings bridge is forming; flat revenue against rising usage would leave the 120-times mark exposed.1 Pulse 2.0 2026-01-21 OpenEvidence raised a $250 million Series D on January 21, 2026 at a $12 billion valuation, led by Thrive Capital and DST Global, providing citation-linked answers drawn only from peer-reviewed medical literature, with about $100 million annual revenue and total funding near $700 million. Open source
  • A regulatory posture emerges. Watch over the next year for any FDA framing, clinical-decision-support classification, or formal liability standard applied to the tool; the absence of one is itself a risk the valuation ignores.1 Pulse 2.0 2026-01-21 OpenEvidence raised a $250 million Series D on January 21, 2026 at a $12 billion valuation, led by Thrive Capital and DST Global, providing citation-linked answers drawn only from peer-reviewed medical literature, with about $100 million annual revenue and total funding near $700 million. Open source
  • Physician usage holds above the 40 percent mark. Sustained or growing penetration confirms the moat; a plateau or decline, especially after any trust incident, would be the first sign the reach premium is fading.2 Healthcare.digital 2026-01-22 The round doubled OpenEvidence's valuation from $6 billion three months earlier; about 40% of US physicians use the free platform across 10,000 hospitals with over 20 million monthly consultations, and revenue comes primarily from pharmaceutical advertising during answer generation, with content partnerships including NEJM, AMA, JAMA and NCCN. Open source
  • The advertising wall stays credible. Any reporting that pharmaceutical sponsorship influenced clinical answers would be the specific event most likely to break the model, since trust is the product.2 Healthcare.digital 2026-01-22 The round doubled OpenEvidence's valuation from $6 billion three months earlier; about 40% of US physicians use the free platform across 10,000 hospitals with over 20 million monthly consultations, and revenue comes primarily from pharmaceutical advertising during answer generation, with content partnerships including NEJM, AMA, JAMA and NCCN. Open source